Arquer Diagnostics (Arquer) is a private, UK-based diagnostics company focused on the development and commercialisation of non-invasive immunoassay diagnostic tests for cancer diagnosis and monitoring.

Arquer’s tests are based on minichromosome maintenance (MCM) protein, a marker for the presence of dividing cancer cells. MCM proteins are excellent biomarkers, being directly involved in cell replication, and when shed into the body fluids can be excellent markers for the presence of cancers.
This patent protected, intellectual property is licensed exclusively from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK.

Our initial focus is on the development of lab based tests for urological (prostate and bladder) cancers. The MCM technology is applicable to a number of cancer types and there is a well-defined requirement for screening tests in number of cancer types for which the MCM technology could offer a clinically relevant test.